Pathstone Family Office’s BlackRock Health Sciences Trust BME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-4,886
Closed -$505K 1243
2022
Q4
$505K Buy
+4,886
New +$208K ﹤0.01% 1094
2021
Q1
Sell
-2,165
Closed -$103K 744
2020
Q4
$103K Buy
+2,165
New +$98.2K ﹤0.01% 381

Other funds holding BME

Pathstone Family Office's BME Position: Q1 2023 in Review

Pathstone Family Office sold out of BlackRock Health Sciences Trust (BME) in Q1 2023, closing a stake of 4,886 shares — an estimated $505K sold.

Pathstone Family Office first reported a position in BME in Q4 2020 and held it in 2 quarters. The position peaked at $505K in Q4 2022. 71 funds tracked by Wall St. Rank hold BME as of Q1 2023.

  • Pathstone Family Office reported no remaining BlackRock Health Sciences Trust position as of Q1 2023 after selling out during the quarter.
  • Pathstone Family Office sold 4,886 BlackRock Health Sciences Trust shares in Q1 2023, an estimated $505K.
  • Pathstone Family Office first reported a position in BlackRock Health Sciences Trust in Q4 2020 and held it in 2 quarters.
  • Pathstone Family Office's BlackRock Health Sciences Trust position peaked at $505K in Q4 2022.
  • 71 funds tracked by Wall St. Rank held BlackRock Health Sciences Trust as of Q1 2023.

Based on Pathstone Family Office's 13F filing for Q1 2023, filed 15 May 2023.